 DarioHealth Corp. Nasdaq: DRIO, a global digital therapeutics DTx innovator, announced today that in an effort to reduce contact between healthcare providers and patients in hospital settings, limit COVID-19 exposure, and preserve personal protective equipment PPE, the U.S. Food and Drug Administration FDA has recognized that home-use blood glucose meters including Darios smartphone-connected metering device may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them. 